Last updated: 11/07/2018 16:10:42
A pilot study to evaluate the efficacy and safety of a combination of antiretroviral drugs including amprenavir with or without ritonavir, two or three nucleoside analogs in HIV-1 infected patients who are in virological escape after a first, second or third line therapy including at least one p ...
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A pilot study to evaluate the efficacy and safety of a combination of antiretroviral drugs including amprenavir with or without ritonavir, two or three nucleoside analogs in HIV-1 infected patients who are in virological escape after a first, second or third line therapy including at least one p ...
Trial description: A pilot study to evaluate the efficacy and safety of a combination of antiretroviral drugs including amprenavir with or without ritonavir, two or three nucleoside analogs in HIV-1 infected patients who are in virological escape after a first, second or third line therapy including at least one p ...
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Comparison of efficacy and safety of amprenavir (apv) versus apviritonavir (rtv) in hiv-1 infected antiretroviral therapy (art) experienced adults. - 8 weeks analysis: prof3020, AGIR study. D. Salmonl, M. Garra D. Jeantils C. Katlama C. Michelet A. Goetsche and JIM. Vauthier on behalf PROF3020-AGIR study group. 8th European Conference on Clinical Aspects and Treatment of HIV Infection 10/28/2001 Athens; Greece
Medical condition
Infection, Human Immunodeficiency Virus
Product
amprenavir
Collaborators
Not applicable
Study date(s)
November 1999 to March 2001
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2001-31-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website